In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Autolus Therapeutics Plc (AUTL). The company’s shares closed yesterday at $29.82.
Phipps noted:
“We believe these results compare very favorably to other CAR-T therapies in adult ALL (summarized in exhibit 1), in terms of both efficacy and safety , and support the advancement of AUTO1 into a pivotal Phase II studies. The company plans to provide an additional update with longer follow-up and additional patients toward the end of the year , likely at ASH, and concurrently launch a global, pivotal Phase II study . Based on the promising initial efficacy and safety , we believe the likelihood of clinical success has increased for AUTO1.”
Phipps has an average return of 4.7% when recommending Autolus Therapeutics Plc.
According to TipRanks.com, Phipps is ranked #2217 out of 5231 analysts.
Currently, the analyst consensus on Autolus Therapeutics Plc is a Moderate Buy with an average price target of $45, a 50.9% upside from current levels. In a report issued on April 1, H.C. Wainwright also maintained a Buy rating on the stock with a $45 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.24 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 58.93K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
